Clinical Trial Update: Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial comparing apatinib to placebo as a third-line treatment for advanced or metastatic gastric cancer has completed (Phase 2/3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Fudan University | Conditions: Gastric Carcinoma | Phase 2, Phase 3 | Status: COMPLETED